Cryoablation in locally advanced pancreatic cancer: A promising ablative frontier

Abstract

Locally advanced pancreatic cancer represents a challenging intersection between potentially resectable and metastatic disease. Despite modern systemic therapies such as modified FOLFIRINOX or gemcitabine plus nab-paclitaxel, survival outcomes remain limited, and local progression continues to be a major driver of morbidity. Ablative techniques – including irreversible electroporation, cryoablation, radiofrequency ablation, microwave ablation, stereotactic body radiotherapy, and intratumoral injection therapies – have emerged as promising modalities to improve local control and potentially stimulate systemic immune responses. Among these modalities, cryoablation stands out due to its unique ability to induce immunogenic cell death while preserving antigenic structures. This minireview synthesizes the current evidence across all ablative strategies, highlighting their mechanisms, clinical outcomes, and immunomodulatory effects, and discusses future integration into multimodal locally advanced pancreatic cancer treatment paradigms.

Key Words: Locally advanced pancreatic cancer; Cryoablation; Irreversible electroporation; Radiofrequency ablation; Microwave ablation; Stereotactic body radiotherapy; Intratumoral injection; Immunotherapy; Multimodal therapy; Immunomodulation

Core Tip: Ablative therapies are transforming the therapeutic landscape of locally advanced pancreatic cancer. Among these, cryoablation stands out for its unique dual mechanism – precise cytoreduction and potent immune activation. Incorporation of ablative modalities into multimodal protocols promises improved local control and novel systemic synergy.

INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest solid malignancies, with a 5-year survival consistently below 10%[1]. Nearly 30%-40% of patients present with locally advanced pancreatic cancer (LAPC), defined by unreconstructable involvement of major mesenteric vasculature – including > 180° encasement of the superior mesenteric artery or celiac axis, or occlusion of the superior mesenteric/portal vein confluence without feasible reconstruction[2]. These anatomical constraints, combined with the tumor’s infiltrative pattern and desmoplastic stroma, render most LAPC tumors biologically and technically unresectable at diagnosis[3].

Despite improvements in induction chemotherapy (modified FOLFIRINOX, gemcitabine/nab-paclitaxel), only 15%-25% of LAPC patients achieve sufficient radiographic or biological response to allow secondary surgical exploration. The majority exhibit persistent perivascular tumor infiltration, limited drug penetration due to stromal density, and hypoxic microenvironments that confer chemoradiotherapy resistance.

Local progression remains a major determinant of morbidity, leading to severe neuropathic pain (via perineural invasion), biliary obstruction, gastric outlet obstruction, portal hypertension, and malnutrition[4]. Importantly, many LAPC patients die from uncontrolled locoregional disease rather than distant metastasis, highlighting the inadequacy of systemic therapy alone for local tumor control[5].

These limitations have accelerated the integration of locoregional ablative therapies into LAPC management. Thermal [radiofrequency ablation (RFA), microwave ablation (MWA)], non-thermal [irreversible electroporation (IRE)], and cryogenic (cryoablation) modalities enable tumor debulking, improved symptom control, and in some cases vascular-adjacent ablation, which is critical in LAPC. Moreover, certain modalities – particularly cryoablation and IRE – induce immunogenic cell death through the release of tumor-associated antigens and damage-associated molecular patterns, promoting dendritic-cell activation and CD8+ T-cell priming[6].

Given PDAC’s traditionally “cold”, immunosuppressive tumor microenvironment, this potential for in situ immunomodulation positions ablative therapies as key components of emerging multimodal treatment frameworks that combine systemic therapy, image-guided ablation, and in selected cases, immunotherapy.

THE RATIONALE FOR ABLATIVE MODALITIES

Conventional chemotherapy and chemoradiotherapy primarily target systemic disease but often fail to control local tumor progression, which can cause pain, biliary obstruction, and vascular invasion. Locoregional ablative techniques extend the therapeutic arsenal by directly inducing tumor necrosis through either thermal, nonthermal, or cryogenic mechanisms. These methods may elicit immunogenic cell death, fostering an “in situ vaccine” effect. The growing evidence for ablation-induced immune activation has repositioned these modalities as functional partners to systemic immunotherapy.

IRE

IRE employs ultrashort high-voltage pulses to create permanent nanopores in cell membranes, causing apoptosis without thermal injury[7]. Its nonthermal mechanism spares connective tissue and major vessels, making it particularly useful in LAPC with vascular involvement.

Clinical series have demonstrated encouraging outcomes. Heger et al[8] reported median overall survival (OS) of 24 months for patients undergoing IRE after induction FOLFIRINOX. A multicenter registry noted 90% local control at 6 months, with manageable complication rates (10%-15%), primarily pancreatitis and vascular thrombosis[9,10].

Immunologically, IRE increases dendritic cell infiltration and T-cell activation while reducing regulatory T-cell fractions, as demonstrated by preclinical models. Early-phase trials are evaluating IRE combined with programmed death 1 blockade (NCT04498767), highlighting its role as an “immune-permissive” ablation[11].

CRYOABLATION: MECHANISMS, EVIDENCE, AND CLINICAL POSITIONING

Biophysical mechanism

Cryoablation induces tumor destruction through repeated freeze-thaw cycles that generate intracellular ice crystals, osmotic shifts, and endothelial injury leading to microthrombosis and ischemic necrosis[12]. This pattern of cell death often preserves antigenic integrity more effectively than thermal ablation, enabling dendritic cell activation and cytotoxic T-cell priming – key principles in cryoimmunology[13].

Recent in vitro work by Baust et al[14] demonstrated that cryoablation maintains structural antigenicity on the PANC-1 cell line and may enhance susceptibility to adjunctive chemotherapy. Their study identified increased apoptotic signaling and improved cellular kill when cryoablation was combined with chemotherapeutic agents, suggesting potential synergy that warrants further clinical evaluation.

While cryoablation minimizes protein denaturation compared with heat-based modalities, robust clinical evidence confirming superior antigen preservation remains limited. The central iceball typically causes complete coagulative necrosis, whereas the periphery contains apoptotic zones.

Clinical safety, feasibility, and complications

Laparoscopic or percutaneous cryoablation under ultrasound or CT guidance allows precise targeting even near major vessels[15]. Wu et al[16] reported 70% complete ablation in 10 LAPC patients with meaningful reductions in pain and carbohydrate antigen (CA) 19-9 levels. Iancu et al[17] later confirmed these findings in 24 patients, noting declines in CA19-9, increases in natural killer cells and tumor necrosis factor alpha, and a median OS of 16.8 months.

The largest contemporary evidence comes from the 2024 systematic review and meta-analysis by Xue et al[18], encompassing over 400 patients with unresectable pancreatic cancer. Their analysis showed: (1) Low perioperative mortality; (2) Acceptable complication rates, primarily pancreatitis, fistula, or bleeding; and (3) Median survival ranging 12-18 months depending on technique and disease stage.

Although complications are generally self-limited, important risks include: (1) Pancreatic fistula; (2) Delayed hemorrhage; (3) Transient hypoglycemia; (4) Local pancreatitis or peripancreatic edema; and (5) Rare reperfusion-related systemic effects.

Careful temperature mapping and controlled thaw cycles remain essential for reducing adverse events.

Immunologic impact and cryoimmunology

Cryoablation promotes release of tumor-associated antigens and damage-associated molecular patterns – including HMGB1, calreticulin, and HSP70 – that drive dendritic cell maturation and Th1-polarized immune responses[4]. Baust et al[14] further demonstrated that sublethal cryogenic stress increases immunogenic surface markers in vitro, supporting the hypothesis that cryoablation may potentiate downstream immune activation.

Despite promising preclinical data, clinical evidence for superior systemic immune activation compared with other ablative modalities remains limited. Early-phase trials (such as NCT04773026) are now evaluating cryoablation in combination with checkpoint inhibitors to test whether this mechanistic potential can translate into improved patient outcomes[19].

TECHNICAL CONSIDERATIONS AND LIMITATIONS

Modern argon-helium cryoprobes enable rapid temperature modulation and precise iceball monitoring via intraoperative ultrasonography. Standard clinical protocols involve dual freeze–thaw cycles of 15-20 minutes. However, limitations persist: (1) Iceball propagation in desmoplastic pancreatic tissue is sometimes unpredictable; (2) Large tumors may require multiple probes; (3) Lesions adjacent to hollow viscera or major ducts pose increased risk; (4) Complications such as fistula or transient endocrine disturbances may occur; and (5) Temperature mapping and gradual thawing remain critical to procedural safety[19].

COMPARATIVE CLINICAL OUTLOOK

Compared with IRE, RFA and MWA, cryoablation provides lower thermal spread, longer procedural control, and potential immunologic advantages[20].

IRE

Supported by the largest dataset (> 800 LAPC patients). Median OS: 24-27 months, superior to most other modalities. Risks include arrhythmia, portal vein thrombosis, and pancreatitis.

RFA

Heat-sink effect limits efficacy near vessels. Risks include pancreatitis, bleeding, duodenal injury. Median OS: Approximately 14-16 months.

MWA

Achieves higher temperatures, faster ablation. Thermal spread remains a concern. Evidence remains smaller than for IRE or RFA.

Cryoablation

Median OS in most series: 14-17 months, as confirmed by Xue et al[18]. Demonstrates significant pain relief and systemic biological activity. Potential synergy with chemotherapy suggested by Baust et al[14]. Overall, cryoablation is a feasible local control method with distinct mechanistic and immunologic features. While early data are encouraging, larger multicenter prospective trials remain necessary to define its comparative role in multimodal LAPC management.

RFA induces thermal coagulative necrosis through high-frequency alternating current, achieving cytotoxic temperatures above 60 °C. Its simplicity and widespread availability made it an early candidate for LAPC management.

However, proximity to major vessels limits efficacy due to the “heat-sink” effect – rapid heat dissipation that protects adjacent vascular structures but spares tumor tissue. Several small series reported modest palliative benefit: (1) Pain reduction; (2) Partial CA19-9 response; and (3) Median OS around 14-16 months. Nonetheless, complications such as duodenal injury, hemorrhage, or pancreatitis occur in up to 10%, restricting its use[21].

RFA remains primarily a palliative cytoreductive option in unresectable cases unsuitable for nonthermal modalities.

MWA generates an electromagnetic field, producing dielectric heating through molecular oscillation. Compared with RFA, MWA achieves higher intratumoral temperatures, larger ablation zones, and shorter procedural times[22].

Clinical series have demonstrated local control rates near 80% for lesions smaller than 3 cm. MWA is less sensitive to the heat-sink effect, making it feasible near moderate vascular structures. Reported complications are mild (transient hyperamylasemia, mild pain).

However, due to pancreatic fragility and limited visualization, MWA in LAPC remains investigational. Integration with intraoperative ultrasonography and contrast-enhanced computed tomography has improved targeting accuracy. MWA’s immunogenicity appears intermediate – greater than RFA but lower than cryoablation or IRE[23].

STEREOTACTIC BODY RADIOTHERAPY

Stereotactic body radiotherapy (SBRT) delivers ablative doses of focused radiation, typically 30-45 Gy in 3-5 fractions, with submillimeter precision. This approach achieves excellent local control (> 80%) and reduced treatment duration compared to conventional chemoradiation[24].

Parikh et al[11] reported median OS of 18-20 months when SBRT followed FOLFIRINOX, comparable to surgical candidates. SBRT induces immunogenic cell death via double-strand DNA breaks and calreticulin exposure, augmenting systemic immunity. Trials combining SBRT with anti-programmed death ligand-1 therapy (NCT04281669) are ongoing, exploring radiation’s potential as an in situ vaccine[16].

Nevertheless, duodenal and biliary toxicity limit dose escalation. Emerging magnetic resonance imaging-guided radiotherapy platforms allow adaptive planning to minimize gastrointestinal exposure, improving tolerance and precision[25].

INTRATUMORAL INJECTION THERAPIES AND EMERGING IMMUNOTHERAPIES

Intratumoral delivery of therapeutic agents has gained renewed interest for LAPC. Willink et al[25] systematically reviewed 52 studies involving 1843 patients. Five main modalities were identified: (1) ¹²⁵I brachytherapy (32 studies, n = 1283); (2) ³²P microbrachytherapy (5 studies, n = 133); (3) ¹⁰³Pd seed therapy (2 studies, n = 26); (4) Immunotherapy injections (9 studies, n = 330); and (5) Chemotherapy microinjections (4 studies, n = 71).

Median OS ranged from 7-16 months depending on modality. Immunotherapy injections (granulocyte-macrophage colony-stimulating factor, dendritic cells, or viral vectors) induced local inflammation and tumor necrosis, albeit with variable toxicity. The combination of cryoablation and intratumoral dendritic-cell injection (cryoimmunotherapy) has shown synergistic activation of T-cell immunity in preclinical pancreatic models, supporting further translational research[25].

Future refinements may include gene-edited cellular payloads or microfluidic catheter systems for precise intratumoral drug distribution.

COMPARATIVE OVERVIEW OF ABLATIVE MODALITIES

Cryoablation and IRE currently demonstrate the best combination of safety, local control, and immunologic potential. SBRT and intratumoral therapies remain attractive adjuncts in multimodal strategies (Table 1).

Table 1 Ablative modalities for locally advanced pancreatic cancer.

Modality	Mechanism	Key advantage	Major limitation	Median overall survival (months)
Irreversible electroporation	Nonthermal apoptosis	Vessel-sparing; effective near major arteries	Requires cardiac synchronization; procedural risks	20-28
Cryoablation	Freeze-thaw necrosis and immune activation	Dual cytoreductive and immunogenic effects	Requires precise imaging guidance; limited trial data	16-20
Radiofrequency ablation	Thermal coagulation	Widely available	Heat-sink effect; duodenal injury risk	14-16
Microwave ablation	Dielectric heating	Larger ablation zones; faster ablation	Limited visibility; pancreatic fragility	15-17
Stereotactic body radiotherapy	Focused high-dose radiation	Non-invasive; high local control	Gastrointestinal toxicity	18-20
Intratumoral injection	Direct delivery (radioisotope, immune, chemotherapy agents)	Immunostimulatory potential	Heterogeneous techniques	7-16

FUTURE PERSPECTIVES: TOWARD IMMUNOABLATIVE ONCOLOGY

The convergence of local ablation and systemic immunotherapy represents a paradigm shift in LAPC management. Ablative therapies may convert immune “cold” tumors into “hot” ones by exposing neoantigens and promoting T-cell infiltration.

Future research directions include: (1) Combination protocols: Cryoablation or IRE followed by immune checkpoint inhibitors or cytokine therapy; (2) Imaging innovation: Magnetic resonance imaging-guided platforms for real-time ablation monitoring; (3) Biomarker discovery: Integration of CA19-9 kinetics and circulating immune signatures for response prediction; and (4) Minimally invasive synergy: Laparoscopic and endoscopic ablation approaches expanding therapeutic reach[9,11,13].

CONCLUSION

LAPC remains a therapeutically challenging disease in which systemic therapy alone is rarely sufficient to achieve durable local control. As multimodal strategies continue to evolve, ablative therapies have emerged as essential contributors to managing persistent locoregional tumor burden. Among these modalities, cryoablation occupies a uniquely advantageous position due to its dual capability of delivering precise cytoreduction while simultaneously preserving tumor antigens that promote robust immunogenic cell death. By facilitating dendritic-cell activation, enhancing CD8+ T-cell infiltration, and modulating the tumor microenvironment, cryoablation has the potential to convert PDAC – traditionally an immune-cold malignancy – into a more immunoresponsive tumor. When integrated with contemporary systemic regimens and, prospectively, with immunotherapeutic agents, cryoablation may meaningfully expand the therapeutic horizon for LAPC. Continued prospective clinical evaluation and optimized patient selection will be critical to defining its role within next-generation multimodality treatment frameworks.